Q3 Loss Widens to $10.29M, Missing Consensus by $1.5M as Phase 3 Costs Climb
GNLX is trading near its 52-week low of $1.77 (6.2% above the low).
Summary
Genelux posted a Q3 net loss of $10.29 million, or $0.23 per share, versus the $8.78 million consensus from five analysts — a clear miss. Operating expenses ran $10.40 million, driven by higher clinical and regulatory costs for the Phase 3 OnPrime/GOG-3076 ovarian cancer trial. This follows the Q2 print on August 13, when the loss widened to $9.5 million on the same trial spending, so the burn is accelerating quarter over quarter. Cash and investments are still expected to fund operations only into 1Q27, and the $100 million at-the-market program filed in March remains the likely funding lever if the runway shortens. The binary event is Phase 3 OnPrime topline data expected in 2H26, with additional lung cancer dose-escalation updates due by year-end 2026.
At the time of this announcement, GNLX was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.9M. The 52-week trading range was $1.77 to $5.89. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.